Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems
September 18, 2024. ZURICH, Switzerland and NEWTON, Massachusetts, US. –GlobeNewswire– Biognosys, a leading inventor and provider of software solutions for mass spectrometry-based proteomics data analysis, today announced the rollout of a Value-added Reselling agreement for Biognosys’ Spectronaut® software with Thermo Fisher Scientific.
The agreement focuses on the co-marketing and co-selling of Biognosys’ Spectronaut software with Thermo Fisher’s mass spectrometry systems for the analysis of data-independent acquisition (DIA) proteomics experiments. The availability of Thermo Fisher’s mass spectrometry instruments with the gold standard for DIA proteomics data analysis, Spectronaut, into a single workflow enables DIA proteomics research with industry-leading depth.
Under the terms of the agreement, Biognosys grants Thermo Fisher the rights to directly quote and sell Spectronaut from their product catalog so that end users can gain access to Thermo Fisher’s mass spectrometry systems and Biognosys’ Spectronaut software via a single offer, issued by Thermo Fisher Scientific. This collaboration enhances the reach of Spectronaut and provides Thermo Fisher customers with simplified access to this market-leading DIA proteomics data analysis software. The new Spectronaut 19 version that was launched at the ASMS 2024 Annual Conference in Anaheim, CA, features deep learning-powered algorithms and improved scalability for the latest generation instruments, including the Orbitrap Astral™ mass spectrometer.
“We are excited to facilitate access to Spectronaut for users of Thermo Fisher mass spectrometry instruments,” said Oliver Rinner, Ph.D., CEO and Founder of Biognosys. “Data analysis remains a critical success factor for mass spectrometry–based proteomics, with huge potential for further gains. With Spectronaut, we have pioneered the transition to DIA as state–of–the–art acquisition method in discovery proteomics. In many exciting areas, the field is still emerging, and we believe that the comparability of results across instrument platforms from different vendors is vital to further progress. Biognosys is committed to providing the best software for instruments from all vendors, and this co-selling agreement with Thermo Fisher is an important step towards greater accessibility for their customers.”
August Specht, Ph.D., Vice President, R&D, Chromatography and Mass Spectrometry, at Thermo Fisher Scientific, added: “We are very pleased to collaborate with Biognosys to equip researchers with powerful workflows for their proteomics research. By making Spectronaut available together with our mass spectrometry systems, we offer our customers a comprehensive, streamlined solution for DIA proteomics.”